BookMatthias Theobald, editor.
Summary: This book offers a comprehensive review of recent advances in cancer immunotherapy, and explores the value and limitations of the most effective current therapeutic strategies and emerging treatment modalities. It discusses in detail the successes achieved using monoclonal antibodies (mAbs), including developments with regard to conjugated mAbs and also bispecific mAbs as novel treatment options for leukemia and solid tumors. It also examines the advances toward personalized immunotherapy, focusing on the effectiveness of adoptive cell therapy using genetically engineered T cells with tumor-associated antigen-specific T-cell receptors and chimeric antigen receptors, as well as the role of tailored vaccines based on the patient's cancer mutanome. Further, it describes the impressive therapeutic results recently achieved with checkpoint inhibitors, and analyzes novel strategies to modulate the immunosuppressive tumor microenvironment. Written by leading international experts and providing up-to-date information on emerging strategies, such as oncolytic virus-based therapy, epigenetic therapy, and combination therapy, the book appeals to all those with an interest in immunotherapy as it comes of age.
Contents:
Current Development of Monoclonal Antibodies in Cancer Therapy
Clinical Experience with Bispecific T-Cell Engagers
Advances and challenges of CAR-modified T cells in clinical trials
Targeting Cancer with Genetically Engineered TCR-T Cells
Tailored Vaccines Based on Patient's Cancer Mutanome
Next-Generation Checkpoint Inhibitors and Immune Agonists.
Location
Version
Call Number
Items